Mann mit Smartphone und Tablet (Symbolbild).
Quelle: - © metamorworks / iStock / Getty Images Plus / Getty Images:
Google
PR Newswire  | 

Cascades Reports Results for the Third Quarter of 2025

PR Newswire

play Anhören
share Teilen
feedback Feedback
copy Kopieren
newsletter
font_big Schrift vergrößern
Cascade Acquisition Corp [Ordinary Sh. 34,24 $ Cascade Acquisition Corp [Ordinary Shares - Class A] Chart +1,24%
Zugehörige Wertpapiere:

KINGSEY FALLS, QC, Nov. 6, 2025 /PRNewswire/ - Cascades Inc. (TSX: CAS) reports its unaudited financial results for the three-month period ended September 30, 2025.

Q3 2025 Highlights

  • Sales of $1,238 million (compared with $1,187 million in Q2 2025 and $1,201 million in Q3 2024);
  • Operating income of $73 million (compared with $36 million in Q2 2025 and $36 million in Q3 2024);
  • Net earnings per common share of $0.29 (compared with a net loss per common share of ($0.03) in Q2 2025 and net earnings per common share of $0.01 in Q3 2024);
  • Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA (A)1) of $159 million (compared with $137 million in Q2 2025 and $140 million in Q3 2024);
  • Adjusted net earnings per common share1 of $0.38 (compared with $0.19 in Q2 2025 and $0.27 in Q3 2024);
  • Net debt1 of $2,023 million as of September 30, 2025 (compared with $2,104 million as of June 30, 2025). Net debt to EBITDA (A) ratio1 of 3.6x, down from 3.8x as of June 30, 2025;
  • The Company now expects to achieve $120 million from the monetization of redundant assets by mid-2026, up from $80 million previously. Including the $31 million of proceeds from the sale of its Flexible Packaging activities on October 8, 2025, a total of $57 million of this objective has been achieved. Proceeds from these sales are expected to go toward debt reduction;
  • Total capital expenditures, net of disposals, of $30 million in Q3 2025, compared to $18 million in Q2 2025 and $34 million in Q3 2024. The Corporation's 2025 forecasted capital expenditures before disposals will be approximately $140 million.

Hugues Simon, President and CEO, commented: "Third quarter consolidated results exceeded our sequential forecast. This was driven by stronger volume, good operational execution, benefits from ongoing profitability initiatives, and favourable raw material and selling price trends. Our packaging business, in particular, had a stronger than expected quarter. This reflected continued positive volume momentum during the quarter, a well executed closure and redistribution of tonnage from the Niagara Falls mill, and a 24% increase in volumes produced at Bear Island, the latter of which achieved 90% of its targeted production ramp up curve in the quarter. As expected, our tissue business similarly had a strong quarter, driven by improvements in volume. At the corporate level, net debt decreased by $81 million sequentially, and leverage fell to 3.6x from 3.8x at the end of the second quarter."

Discussing near-term outlook, Mr. Simon commented, "We are expecting fourth quarter performance to be stable sequentially on a consolidated basis. Notwithstanding favourable raw material and selling price trends and a continuation of good demand levels in October, we remain cautious in packaging. To this end, we are forecasting lower sequential results for this business, driven by our current expectation that volume will decrease in seasonally softer December. For tissue, we expect the momentum of sequentially stronger results to continue in the fourth quarter, driven by lower maintenance and favourable raw material costs. Looking further ahead, we are focused on achieving our strategic objectives. Despite the ongoing uncertainty in the current economic environment, we are making good progress across many of these initiatives. We are confident that the fundamentals for our Company are strong, and are steadfast in our commitment to continue to improve the financial profile, level of operational and commercial excellence and growth momentum of our Company."

1

Some information represents non-IFRS Accounting Standards Financial measures, other financial measures or non-IFRS Accounting Standards ratios which are not standardized under IFRS Accounting Standards and therefore might not be comparable to similar financial measures disclosed by other corporations. Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Financial Summary

Selected consolidated information

(in millions of Canadian dollars, except amounts per common share) (unaudited)

Q3 2025

Q2 2025

Q3 2024





Sales

1,238

1,187

1,201

As Reported




Operating income

73

36

36

Net earnings (loss)

29

(3)

1

  per common share (basic)

$0.29

($0.03)

$0.01

Adjusted1




Earnings before interest, taxes, depreciation and amortization (EBITDA (A))

159

137

140

Net earnings

39

19

27

  per common share (basic)

$0.38

$0.19

$0.27

Margin (EBITDA (A) / Sales)

12.8 %

11.5 %

11.7 %

Net debt 1

2,023

2,104

2,039

Net debt / EBITDA (A) ratio 1

             3.6x

             3.8x

             4.3x

Segmented sales

(in millions of Canadian dollars) (unaudited)

Q3 2025

Q2 2025

Q3 2024





Packaging Products

797

763

773

Tissue Papers

412

392

390

Inter-segment sales, Corporate, Recovery and Recycling activities

29

32

38

Sales

1,238

1,187

1,201

Segmented operating income (loss)

(in millions of Canadian dollars) (unaudited)

Q3 2025

Q2 2025

Q3 2024





Packaging Products

73

46

41

Tissue Papers

30

25

24

Corporate, Recovery and Recycling activities

(30)

(35)

(29)

Operating income

73

36

36

Segmented EBITDA (A)1

(in millions of Canadian dollars) (unaudited)

Q3 2025

Q2 2025

Q3 2024





Packaging Products

136

119

117

Tissue Papers

46

38

43

Corporate, Recovery and Recycling activities

(23)

(20)

(20)

EBITDA (A)1

159

137

140

1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Analysis of results for the three-month period ended September 30, 2025 (compared to the same period last year)

The Corporation's third quarter sales of $1,238 million increased by $37 million compared with the same period last year. This increase was driven by consolidated net benefits of $43 million from higher selling prices and $7 million from a more favourable foreign exchange. These were partially offset by $12 million from lower volumes mainly in the Packaging Products segment.

The third quarter EBITDA (A)1 totaled $159 million, an increase of $19 million, or 14%, from the $140 million generated in the same period last year. This increase was driven by net benefits of $43 million from higher selling prices and by lower raw material costs of $19 million, mainly in the Packaging Products segment. These were partially offset by net impacts of $38 million from higher production and energy costs and $5 million from lower volumes mainly in the Packaging Products segment.

The main specific items, before income taxes, that impacted our third quarter of 2025 operating income and/or net earnings were:

  • $10 million for an additional environmental provision related to the closure of a plant in Canada in 2024 (operating income and net earnings);
  • $6 million of restructuring costs related to a plant closure in the United States and corporate organizational changes (operating income and net earnings);
  • $4 million unrealized gain on financial instruments (operating income and net earnings).

For the three-month period ended September 30, 2025, the Corporation posted net earnings of $29 million, or $0.29 per common share, compared to net earnings of $1 million, or $0.01 per common share, in the same period of 2024. On an adjusted basis1, the Corporation posted net earnings of $39 million in the third quarter of 2025, or $0.38 per common share, compared to net earnings of $27 million, or $0.27 per common share, in the same period of 2024.

1 Please refer to the "Supplemental Information on Non-IFRS Accounting Standards Measures and Other Financial Measures" section for a complete reconciliation.

Dividend on common shares and normal course issuer bid

The Board of Directors of Cascades declared a quarterly dividend of $0.12 per common share to be paid on December 4, 2025 to shareholders of record at the close of business on November 20, 2025. This dividend is an "eligible dividend" as per the Income Tax Act (R.C.S. (1985), Canada). During the third quarter of 2025, Cascades purchased no common shares for cancellation.

2025 Third Quarter Results Conference Call Details

Management will discuss the 2025 third quarter financial results during a conference call today at 9:00 a.m. ET. The call can be accessed by dialing 1-800-990-4777 (international 1-289-819-1299). The conference call, including the investor presentation, will be broadcast live on the Cascades website (www.cascades.com) under the "Investors" section. A replay of the call will be available on the Cascades website and may also be accessed by phone until December 6, 2025 by dialing 1-888-660-6345 (international 1-289-819-1450), access code 72641 #.

Founded in 1964, Cascades offers sustainable, innovative and value-added packaging, hygiene and recovery solutions. The company employs approximately 9,300 women and men across a network of 65 operating facilities, including 17 Recovery and Recycling facilities which are part of Corporate Activities and joint ventures managed by the Corporation, in North America. Driven by its participative management, half a century of experience in recycling, and continuous research and development efforts, Cascades continues to provide innovative products that customers have come to rely on, while contributing to the well-being of people, communities and the entire planet. Cascades' shares trade on the Toronto Stock Exchange under the ticker symbol CAS. Certain statements in this release, including statements regarding future results and performance, are forward-looking statements based on current expectations. The accuracy of such statements is subject to a number of risks, uncertainties and assumptions that may cause actual results to differ materially from those projected, including, but not limited to, the effect of general economic conditions, decreases in demand for the Corporation's products, increases in raw material costs, fluctuations in selling prices and adverse changes in general market and industry conditions and other factors.

CONSOLIDATED BALANCE SHEETS

(in millions of Canadian dollars) (unaudited)

September 30,
2025

December 31,
2024

Assets



Current assets



Cash and cash equivalents

73

27

Accounts receivable

502

469

Current income tax assets

12

4

Inventories

648

685

Current portion of financial assets

7

1


1,242

1,186

Long-term assets



Investments in associates and joint ventures

81

97

Property, plant and equipment

2,674

2,847

Intangible assets with finite useful life

33

41

Financial assets

5

Other assets

110

105

Deferred income tax assets

225

220

Goodwill and other intangible assets with indefinite useful life

495

504


4,865

5,000

Liabilities and Equity



Current liabilities



Bank loans and advances

1

10

Trade and other payables

701

748

Current income tax liabilities

4

2

Current portion of unsecured senior notes

175

Current portion of long-term debt

68

67

Current portion of provisions for charges

18

42

Current portion of financial liabilities and other liabilities

22

43


814

1,087

Long-term liabilities



Long-term debt

2,027

1,871

Provisions for charges

59

58

Financial liabilities

10

Other liabilities

74

80

Deferred income tax liabilities

142

133


3,126

3,229

Equity



Capital stock

618

616

Contributed surplus

17

16

Retained earnings

1,020

1,019

Accumulated other comprehensive income

52

73

Equity attributable to Shareholders

1,707

1,724

Non-controlling interests

32

47

Total equity

1,739

1,771


4,865

5,000

CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)


For the 3-month periods
ended September 30,

For the 9-month periods
ended September 30,

(in millions of Canadian dollars, except per common share amounts and number of
  common shares) (unaudited)

2025

2024

2025

2024

Sales

1,238

1,201

3,579

3,490






Supply chain and logistic

744

736

2,125

2,126

Wages and employee benefits expenses

269

267

824

809

Depreciation and amortization

74

70

215

206

Maintenance and repair

62

58

193

180

Other operational costs

4

16

20

Impairment charges

7

24

9

Other loss (gain)

10

24

15

27

Restructuring costs

6

5

12

38

Unrealized gain on derivative financial instruments

(4)

(2)

(4)

(4)

Operating income

73

36

159

79

Financing expense

35

36

104

108

Share of results of associates and joint ventures

(5)

(5)

(11)

(14)

Earnings (loss) before income taxes

43

5

66

(15)

Provision for (recovery of) income taxes

8

(1)

16

(8)

Net earnings (loss) including non-controlling interests for the period

35

6

50

(7)

Net earnings attributable to non-controlling interests

6

5

17

11

Net earnings (loss) attributable to Shareholders for the period

29

1

33

(18)

Net earnings (loss) per common share





Basic

$0.29

$0.01

$0.33

($0.18)

Diluted

$0.29

$0.01

$0.33

($0.18)

Weighted average basic number of common shares outstanding

101,257,276

100,988,040

101,135,376

100,824,800

Weighted average number of diluted common shares

101,338,740

101,042,159

101,309,725

101,042,799

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)


For the 3-month periods
ended September 30,

For the 9-month periods
ended September 30,

(in millions of Canadian dollars) (unaudited)

2025

2024

2025

2024

Net earnings (loss) including non-controlling interests for the period

35

6

50

(7)

Other comprehensive income (loss)





Items that may be reclassified subsequently to earnings





Translation adjustments





Change in foreign currency translation of foreign subsidiaries

24

(14)

(80)

24

Change in foreign currency translation related to net investment hedging activities

(13)

6

61

(9)

Cash flow hedges





Change in fair value of commodity derivative financial instruments

(1)

1

(1)

1

Recovery of (provision for) income taxes

2

(1)

(3)

1


12

(8)

(23)

17

Items that are not released to earnings





Actuarial gain (loss) on employee future benefits

6

(4)

5

7

Recovery of (provision for) income taxes

(1)

1

(1)

(2)


5

(3)

4

5

Other comprehensive income (loss)

17

(11)

(19)

22

Comprehensive income (loss) including non-controlling interests for the period

52

(5)

31

15

Comprehensive income attributable to non-controlling interests for the period

6

5

15

12

Comprehensive income (loss) attributable to Shareholders for the period

46

(10)

16

3

CONSOLIDATED STATEMENTS OF EQUITY


For the 9-month period ended September 30, 2025

(in millions of Canadian dollars) (unaudited)

CAPITAL
STOCK

CONTRIBUTED
SURPLUS

RETAINED
EARNINGS

ACCUMULATED
OTHER
COMPREHENSIVE
INCOME

TOTAL
EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS

NON-
CONTROLLING
INTERESTS

TOTAL
EQUITY

Balance - Beginning of period

616

16

1,019

73

1,724

47

1,771

Comprehensive income (loss)








Net earnings

33

33

17

50

Other comprehensive income (loss)

4

(21)

(17)

(2)

(19)


37

(21)

16

15

31

Dividends

(36)

(36)

(30)

(66)

Stock options expense

1

1

1

Issuance of common shares upon exercise of stock options

2

2

2

Balance - End of period

618

17

1,020

52

1,707

32

1,739










For the 9-month period ended September 30, 2024

(in millions of Canadian dollars) (unaudited)

CAPITAL
STOCK

CONTRIBUTED
SURPLUS

RETAINED
EARNINGS

ACCUMULATED
OTHER
COMPREHENSIVE
INCOME

TOTAL
EQUITY
ATTRIBUTABLE TO
SHAREHOLDERS

NON-
CONTROLLING
INTERESTS

TOTAL
EQUITY

Balance - Beginning of period

613

15

1,096

15

1,739

42

1,781

Comprehensive income (loss)








Net earnings (loss)

(18)

(18)

11

(7)

Other comprehensive income

5

16

21

1

22


(13)

16

3

12

15

Dividends

(36)

(36)

(12)

(48)

Stock options expense

2

2

2

Issuance of common shares upon exercise of stock options

3

(1)

2

2

Acquisition of non-controlling interests

(2)

(2)

(2)

Balance - End of period

616

16

1,045

31

1,708

42

1,750

CONSOLIDATED STATEMENTS OF CASH FLOWS


For the 3-month periods
ended September 30,

For the 9-month periods
ended September 30,

(in millions of Canadian dollars) (unaudited)

2025

2024

2025

2024

Operating activities





Net earnings (loss) attributable to Shareholders for the period

29

1

33

(18)

Adjustments for:





  Financing expense

35

36

104

108

  Depreciation and amortization

74

70

215

206

  Impairment charges

7

24

9

  Other loss (gain)

10

24

15

27

  Restructuring costs

6

5

12

38

  Unrealized gain on derivative financial instruments

(4)

(2)

(4)

(4)

  Provision for (recovery of) income taxes

8

(1)

16

(8)

  Share of results of associates and joint ventures

(5)

(5)

(11)

(14)

  Net earnings attributable to non-controlling interests

6

5

17

11

  Net financing expense paid

(33)

(48)

(107)

(113)

  Net income taxes paid

(2)

(1)

(9)

(4)

  Dividends received

19

26

9

  Payments, net of provisions, for charges and other liabilities

(27)

(15)

(78)

(61)


116

76

253

186

Changes in non-cash working capital components

65

26

(57)

(68)


181

102

196

118

Investing activities





Payments for property, plant and equipment

(30)

(35)

(110)

(116)

Proceeds from disposals of property, plant and equipment

1

26

18

Change in intangible and other assets

(1)

(20)


(31)

(34)

(84)

(118)

Financing activities





Bank loans and advances

(2)

4

(9)

7

Change in credit facilities

(38)

(22)

(146)

63

Change in credit facilities without recourse to the Corporation

(28)

(6)

93

12

Issuance of unsecured senior notes, net of related expenses

541

Repurchase of unsecured senior notes

(456)

Increase in delayed draw unsecured term loan credit facility

36

Payments of other long-term debt, including lease obligations (2025 - $59 million for the
    9-month period ($20 million for the 3-month period); 2024 - $50 million for the 9-month period
   ($15 million for the 3-month period))

(21)

(17)

(61)

(54)

Issuance of common shares upon exercise of stock options

2

2

Dividends paid to non-controlling interests

(3)

(4)

(30)

(12)

Acquisition of non-controlling interests

(3)

Dividends paid to the Corporation's Shareholders

(12)

(12)

(36)

(36)


(104)

(57)

(66)

(21)

Net change in cash and cash equivalents during the period

46

11

46

(21)

Currency translation on cash and cash equivalents

1

1

Cash and cash equivalents - Beginning of the period

26

23

27

54

Cash and cash equivalents - End of the period

73

34

73

34

SEGMENTED INFORMATION

In the fourth quarter of 2024, the Corporation announced organizational changes designed to support its strategic growth. These changes involve the combination of the Containerboard and Specialty Products activities into a single operational unit. Since January 2025, the Corporation's operations are managed in two segments: Packaging Products and Tissue Papers. The comparative figures have been restated to conform with the current year's presentation. The accounting policies of the reportable segments are the same as the Corporation's accounting policies described in the most recent Audited Consolidated Financial Statements for the year ended December 31, 2024.

The Corporation's operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker (CODM). The Chief Executive Officer has authority for resource allocation and management of the Corporation's performance and is therefore the CODM. The CODM assesses the performance of each reportable segment based on sales and earnings before interest, taxes, depreciation and amortization, adjusted to exclude specific items (EBITDA (A)). The CODM considers EBITDA (A) to be the best performance measure of the Corporation's activities.

Sales for each segment are prepared on the same basis as those of the Corporation. Inter-segment operations are recorded on the same basis as sales to third parties, which are at fair market value.

EBITDA (A) does not have a standardized meaning under IFRS Accounting Standards; accordingly, it may not be comparable to similarly named measures used by other companies. Investors should not view EBITDA (A) as an alternative measure to, for example, net earnings, or as a measure of operating results, which are IFRS Accounting Standards measures.

Sales by business segment are shown in the following table:


SALES

For the 3-month periods ended September 30
(in millions of Canadian dollars) (unaudited)

2025

2024

Total

Inter-segment

External

Total

Inter-segment

External

Packaging Products

797

(13)

784

773

(12)

761

Tissue Papers

412

412

390

390

Corporate, Recovery and Recycling activities

69

(27)

42

90

(40)

50


1,278

(40)

1,238

1,253

(52)

1,201

 


SALES

For the 9-month periods ended September 30
(in millions of Canadian dollars) (unaudited)

2025

2024

Total

Inter-segment

External

Total

Inter-segment

External

Packaging Products

2,322

(37)

2,285

2,227

(37)

2,190

Tissue Papers

1,168

1,168

1,154

(1)

1,153

Corporate, Recovery and Recycling activities

215

(89)

126

261

(114)

147


3,705

(126)

3,579

3,642

(152)

3,490

EBITDA (A) by business segment is reconciled to IFRS Accounting Standards measure, namely operating income (loss), and is shown in the following table:


For the 3-month period ended September 30, 2025

(in millions of Canadian dollars) (unaudited)

Packaging

Products

Tissue
Papers

Corporate,
Recovery and
Recycling activities

Consolidated

Operating income (loss)

73

30

(30)

73

Depreciation and amortization

48

16

10

74

Other loss

10

10

Restructuring costs

5

1

6

Unrealized gain on derivative financial instruments

(4)

(4)

EBITDA (A)

136

46

(23)

159

Supply chain and logistic and Wage and employee benefits expenses included in
   operating income (loss)

619

345

49

1,013

 


For the 3-month period ended September 30, 2024

(in millions of Canadian dollars) (unaudited)

Packaging

Products

Tissue
Papers

Corporate,
Recovery and
Recycling
activities

Consolidated

Operating income (loss)

41

24

(29)

36

Depreciation and amortization

44

16

10

70

Impairment charges

4

3

7

Other loss

24

24

Restructuring costs

5

5

Unrealized gain on derivative financial instruments

(1)

(1)

(2)

EBITDA (A)

117

43

(20)

140

Supply chain and logistic and Wage and employee benefits expenses included in
   operating income (loss)

621

325

57

1,003

 


For the 9-month period ended September 30, 2025

(in millions of Canadian dollars) (unaudited)

Packaging
Products

Tissue
Papers

Corporate,
Recovery and
Recycling activities

Consolidated

Operating income (loss)

179

79

(99)

159

Depreciation and amortization

143

43

29

215

Impairment charges

23

1

24

Other loss (gain)

16

(1)

15

Restructuring costs

6

6

12

Unrealized gain on derivative financial instruments

(3)

(1)

(4)

EBITDA (A)

364

121

(64)

Für dich aus unserer Redaktion zusammengestellt

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.


Weitere Artikel des Autors

Themen im Trend